What happened
GL Pharm Tech updated a previously disclosed supply contract with Okura Bioscience Co., Ltd., now worth US$728K, about 16.1% of its recent annual revenue, running through Sep 2026.
For context, this single contract equals about 16.1% of the company's most recent annual revenue.
| Counterparty | Okura Bioscience Co., Ltd. |
|---|---|
| Contract value | US$728K |
| vs. recent revenue | 16.1% |
| Through | Sep 2026 (from Dec 2022) |
| Filed | 2026-09-21, [Amended] Supply contract signed |
| Source | DART rcept 20260921900523 → open original filing |
Source: DART. Information only, not investment advice.